First Time Loading...

Entrada Therapeutics Inc
NASDAQ:TRDA

Watchlist Manager
Entrada Therapeutics Inc Logo
Entrada Therapeutics Inc
NASDAQ:TRDA
Watchlist
Price: 14.36 USD 2.21% Market Closed
Updated: May 10, 2024

Entrada Therapeutics Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Entrada Therapeutics Inc
Interest Income Expense Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Entrada Therapeutics Inc
NASDAQ:TRDA
Interest Income Expense
$15.2m
CAGR 3-Years
377%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$1.8B
CAGR 3-Years
8%
CAGR 5-Years
-7%
CAGR 10-Years
-19%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$757m
CAGR 3-Years
35%
CAGR 5-Years
0%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.9B
CAGR 3-Years
-44%
CAGR 5-Years
-30%
CAGR 10-Years
-16%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$563.1m
CAGR 3-Years
78%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$221.8m
CAGR 3-Years
-13%
CAGR 5-Years
75%
CAGR 10-Years
N/A

See Also

What is Entrada Therapeutics Inc's Interest Income Expense?
Interest Income Expense
15.2m USD

Based on the financial report for Dec 31, 2023, Entrada Therapeutics Inc's Interest Income Expense amounts to 15.2m USD.

What is Entrada Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
377%

Over the last year, the Interest Income Expense growth was 479%. The average annual Interest Income Expense growth rates for Entrada Therapeutics Inc have been 377% over the past three years .